PT  - JOURNAL ARTICLE
AU  - Ren, Shengxiang
AU  - Wang, Xicheng
AU  - Han, Bao-Hui
AU  - Pan, Yueyin
AU  - Zhao, Jun
AU  - Cheng, Yufeng
AU  - Hu, Sheng
AU  - Liu, Tianshu
AU  - Li, Yalun
AU  - Cheng, Ying
AU  - Feng, Jifeng
AU  - Yi, Shanyong
AU  - Gu, Shanzhi
AU  - Gao, Shegan
AU  - Luo, Yongzhong
AU  - Liu, Ying
AU  - Liu, Caigang
AU  - Duan, Huijie
AU  - Wang, Shuni
AU  - Yang, Xinfeng
AU  - Fan, Jia
AU  - Zhou, Caicun
TI  - First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
AID  - 10.1136/jitc-2023-007227
DP  - 2024 Feb 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e007227
VI  - 12
IP  - 2
4099  - http://jitc.bmj.com/content/12/2/e007227.short
4100  - http://jitc.bmj.com/content/12/2/e007227.full
SO  - J Immunother Cancer2024 Feb 01; 12
AB  - Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.